Alnylam reports 60%–64% mutant huntingtin reduction with brezosiran

Alnylam Pharmaceuticals reported that patients receiving the highest dose of experimental Huntington’s disease drug brezosiran had average reductions of 60% or 64% in mutant huntingtin levels in spinal fluid, depending on the assay used. The results came from…